MIF promotor polymorphisms are associated with worse survival in prostate cancer, with the -173 G/C SNP correlating with increased disease incidence and -794 CATT7 correlating with an increased 5-year recurrence risk [204]. Here, MIF is linked to prostate carcinoma.